每日医刻｜礼来起诉四家药企；默克洽谈收购生物制药公司SpringWorks

财健道2025-04-27

将“财健道”设为星标持续关注，不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。映恩生物宣布，与阿斯利康建立合作，双方将就映恩生物自主研发的HER3ADC创新药DB-1310与阿斯利康的第三代EGFR抑制剂奥希替尼的联合疗法开展临床探索。2总金额超1.12亿美元，复宏汉霖就H药与Lotus达成韩国独家授权合作4月25日，复宏汉霖宣布，与美时化学制药全资子公司Lotus签署授权许可协议，授予...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530880874?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-27 11:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530880874","market":"us","top_or_hot":-1,"title":"每日医刻｜礼来起诉四家药企；默克洽谈收购生物制药公司SpringWorks","media":"财健道","content":"<div>\n<p>将“财健道”设为星标持续关注，不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。映恩生物宣布，与阿斯利康建立合作，双方将就映恩生物自主研发的HER3ADC创新药DB-1310与阿斯利康的第三代EGFR抑制剂奥希替尼的联合疗法开展临床探索。2总金额超1.12亿美元，复宏汉霖就H药与Lotus达成韩国独家授权合作4月25日，复宏汉霖宣布，与美时化学制药全资子公司Lotus签署授权许可协议，授予...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427124546a6c9fc4d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>每日医刻｜礼来起诉四家药企；默克洽谈收购生物制药公司SpringWorks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n每日医刻｜礼来起诉四家药企；默克洽谈收购生物制药公司SpringWorks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-27 11:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427124546a6c9fc4d&s=b><strong>财健道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>将“财健道”设为星标持续关注，不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。映恩生物宣布，与阿斯利康建立合作，双方将就映恩生物自主研发的HER3ADC创新药DB-1310与阿斯利康的第三代EGFR抑制剂奥希替尼的联合疗法开展临床探索。2总金额超1.12亿美元，复宏汉霖就H药与Lotus达成韩国独家授权合作4月25日，复宏汉霖宣布，与美时化学制药全资子公司Lotus签署授权许可协议，授予...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427124546a6c9fc4d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0672654240.SGD","symbol_name":"FTIF - Franklin US Opportunities A Acc SGD-H1","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427124546a6c9fc4d&s=b","article_id":"2530880874","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427124546a6c9fc4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530880874","pubTimestamp":1745725880,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"将“财健道”设为星标持续关注，不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。4德国默克洽谈收购生物制药公司SpringWorks4月25日，德国默克集团证实，与生物制药公司SpringWorksTherapeutics就潜在收购事宜开展后期洽谈，讨论的收购价为每股约47美元。默克集团表示，双方尚未做出最终决定，也未签订有约束力协议。5礼来起诉四家药企日前，据媒体报道，礼来正在起诉四家远程医疗公司，因为他们销售了礼来减重药物Zepbound和糖尿病治疗药物Mounjaro的仿制版本。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","MRK":"默沙东","LLY":"礼来","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4559":"巴菲特持仓","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","SG9999015978.USD":"利安颠覆性创新基金A","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","BK4581":"高盛持仓","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC"},"translate_title":"Daily Medical Engraving | Eli Lilly sued four pharmaceutical companies; Merck talks to buy biopharma company SpringWorks","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"MRK":1},"content_text":"将“财健道”设为星标持续关注，不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。映恩生物宣布，与阿斯利康建立合作，双方将就映恩生物自主研发的HER3ADC创新药DB-1310与阿斯利康的第三代EGFR抑制剂奥希替尼的联合疗法开展临床探索。2总金额超1.12亿美元，复宏汉霖就H药与Lotus达成韩国独家授权合作4月25日，复宏汉霖宣布，与美时化学制药全资子公司Lotus签署授权许可协议，授予其在韩国对公司自主开发的抗PD-1单抗H药汉斯状®（斯鲁利单抗）包括ES-SCLC在内的多项适应症的独家商业化和半独家开发权益。根据协议，复宏汉霖将负责H药在韩国上市后的产品生产和供应，并将从此次交易中获得500万美元的首付款、可达950万美元的监管里程碑付款、可达9750万美元的商业化里程碑付款及两位数比例的合作区域净销售额特许权使用费。3华东医药一季报：营收107.36亿元，同比增长3.12%近日，华东医药发布2025年第一季度业绩报告。报告显示，第一季度公司实现营业收入107.36亿元，同比增长3.12%；实现归属于上市公司股东的净利润9.15亿元，同比增长6.06%。4德国默克洽谈收购生物制药公司SpringWorks4月25日，德国默克集团证实，与生物制药公司SpringWorksTherapeutics就潜在收购事宜开展后期洽谈，讨论的收购价为每股约47美元。默克集团表示，双方尚未做出最终决定，也未签订有约束力协议。5礼来起诉四家药企日前，据媒体报道，礼来正在起诉四家远程医疗公司，因为他们销售了礼来减重药物Zepbound和糖尿病治疗药物Mounjaro的仿制版本。独学而无友，则孤陋而寡闻。欢迎更多读者向《财健道》分享对于医药行业的困惑、见解或期待，添加财健道小助手微信：13581763450，通过实名认证后加入读者群。更多商务合作请咨询：Sylvie-1123。扫描下方二维码添加小助手微信","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,policyRegulatory,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530880874","isCrawlerRequest":true}